Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus rituximab for newly diagnosed pemphigus vulgaris
IRCT20260814070645N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ocrelizumab and rituximab in pemphigus vulgaris (PV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Pemphigus Disease Area Index at month 12, Complete remission and 3 more. Started Sep 2026; status: recruiting.
02
Drugs
ocrelizumabrituximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on IRCT20260814070645N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260814070645N1.